ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 202 filers reported holding ACADIA PHARMACEUTICALS INC in Q2 2019. The put-call ratio across all filers is 1.99 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $19,000 | +11.8% | 394 | 0.0% | 0.00% | – |
| Q1 2020 | $17,000 | -65.3% | 394 | -67.2% | 0.00% | – |
| Q4 2019 | $49,000 | +36.1% | 1,200 | +20.0% | 0.00% | – |
| Q3 2019 | $36,000 | +33.3% | 1,000 | 0.0% | 0.00% | – |
| Q2 2019 | $27,000 | 0.0% | 1,000 | 0.0% | 0.00% | – |
| Q1 2019 | $27,000 | -3.6% | 1,000 | -20.0% | 0.00% | – |
| Q1 2018 | $28,000 | -26.3% | 1,250 | 0.0% | 0.00% | – |
| Q4 2017 | $38,000 | +35.7% | 1,250 | +66.7% | 0.00% | – |
| Q3 2017 | $28,000 | +33.3% | 750 | 0.0% | 0.00% | – |
| Q2 2017 | $21,000 | -69.6% | 750 | -62.5% | 0.00% | – |
| Q1 2017 | $69,000 | +19.0% | 2,000 | 0.0% | 0.00% | – |
| Q4 2016 | $58,000 | +262.5% | 2,000 | +300.0% | 0.00% | – |
| Q2 2016 | $16,000 | -42.9% | 500 | -50.0% | 0.00% | – |
| Q1 2016 | $28,000 | +33.3% | 1,000 | +66.7% | 0.00% | – |
| Q4 2015 | $21,000 | +23.5% | 600 | +20.0% | 0.00% | – |
| Q3 2015 | $17,000 | +30.8% | 500 | +66.7% | 0.00% | – |
| Q2 2015 | $13,000 | – | 300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
| Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
| RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
| Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
| Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
| EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
| EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
| SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |